New Tendencies in Development of ALK-TKIs for Treatment of ALK-Rearranged NSCLC

ALK-rearrangements are oncogenic drivers in 3-5% of NSCLC and various cancers. Today, six TKI inhibitors are available for patients with advanced ALK-rearranged non-small cell lung cancer. In this MEDtalk, Edyta Maria Urbanska, Rigshospitalet, Copenhagen, Denmark, gives an overview of new tendencies in the development of ALK-TKIs.